Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

LARKSPUR BIOSCIENCES

LARKSPUR BIOSCIENCES logo

Larkspur Biosciences is building the next precision immunotherapies to outsmart cancer. Larkspur’s approach targets the unique ways that tumors hijack the immune system by developing precision immunotherapies for molecularly defined patient populations in order to overcome these bottlenecks. The company is advancing its first-in-class programs to outsmart the tumor and enable robust and sustained immune responses in colorectal cancer (CRC) and beyond. LarkX, the company’s discovery platform, leverages tumor genetics and immune phenotypes from patient-derived data to fuel its pipeline and offers the opportunities to address multiple types of cancer.